Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetics of Warfarin Induction and Inhibition

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects will be 18-60 years old.~* Women of child bearing age must be willing to use measures to avoid conception during the study period.~* Subjects must agree not to take any known substrates, inhibitors, inducers or activators of either CYP2C9 or CYP3A4 from 1 week prior to the start of each study through the last day of study.~Exclusion Criteria:~* Current cigarette smoker~* Abnormal renal, liver function tests, physical exam, or recent history of hepatic, renal, gastrointestinal or neoplastic disease.~* Allergy to warfarin, fluconazole or rifampin and other chemically related drugs.~* Recent ingestion (\< 1 week) of any medication known to be metabolized by or alter CYP2C9 or CYP3A4 activity.~* A positive pregnancy test at the time of the pharmacokinetic study.~* Lab tests indicative of abnormal blood clotting capacity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- CYP2C9*1/*1 Genotype (Type: OTHER): This genotype is considered the wild type genotype. Individuals with the CYP2C9\*1/\*1 genotype have two \*1 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
- CYP2C9*1B/*1B Haplotype (Type: OTHER): Individuals with the CYP2C9\*1B/\*1B haplotype have two CYP2C9\*1B alleles and participated in the following interventions: Control - Warfarin only and Rifampin - Warfarin.
- CYP2C9*1/*3 Genotype (Type: OTHER): Individuals with the CYP2C9\*1/\*3 genotype have one \*1 allele and one \*3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
- CYP2C9*2/*3 Genotype (Type: OTHER): Individuals with the CYP2C9\*2/\*3 genotype have one \*2 and one \*3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
- CYP2C9*3/*3 Genotype (Type: OTHER): Individuals with the CYP2C9\*3/\*3 genotype have two \*3 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.

Based on this trial design, predict the completion outcome and termination type (if applicable).